Loss of the Birt–Hogg–Dube Tumor Suppressor Results in Apoptotic Resistance due to Aberrant TGFb-Mediated Transcription

DSpace/Manakin Repository

Loss of the Birt–Hogg–Dube Tumor Suppressor Results in Apoptotic Resistance due to Aberrant TGFb-Mediated Transcription

Citable link to this page

. . . . . .

Title: Loss of the Birt–Hogg–Dube Tumor Suppressor Results in Apoptotic Resistance due to Aberrant TGFb-Mediated Transcription
Author: Cash, T P; Gruber, J J; Hartman, T R; Henske, Elizabeth Petri; Simon, M. C.

Note: Order does not necessarily reflect citation order of authors.

Citation: Cash, T. P., J. J. Gruber, T. R. Hartman, E. P. Henske, and M. C. Simon. 2011. Loss of the Birt–Hogg–Dube´ tumor suppressor results in apoptotic resistance due to aberrant TGFb-mediated transcription. Oncogene 30(22): 2534-2546.
Full Text & Related Files:
Abstract: Birt–Hogg–Dubé (BHD) syndrome is an inherited cancer susceptibility disease characterized by skin and kidney tumors, as well as cystic lung disease, which results from loss-of-function mutations in the BHD gene. BHD is also inactivated in a significant fraction of patients with sporadic renal cancers and idiopathic cystic lung disease, and little is known about its mode of action. To investigate the molecular and cellular basis of BHD tumor suppressor activity, we generated mutant Bhd mice and embryonic stem cell lines. BHD-deficient cells exhibited defects in cell-intrinsic apoptosis that correlated with reduced expression of the BH3-only protein Bim, which was similarly observed in all human and murine BHD-related tumors examined. We further demonstrate that Bim deficiency in Bhd−/− cells is not a consequence of elevated mTOR or ERK activity, but results instead from reduced Bim transcription associated with a general loss of TGFβ-mediated transcription and chromatin modifications. In aggregate, this work identifies a specific tumor suppressive mechanism for BHD in regulating TGFβ-dependent transcription and apoptosis, which has implications for the development of targeted therapies.
Published Version: doi:10.1038/onc.2010.628
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109270/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5978686

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters